Resultados: 265

    The advisory committee on immunization practices’ interim recommendation for use of Pfizer-Biontech Covid-19 vaccine in children aged 5–11 years: United States, november 2021

    MMWR recomm. rep; 70 (45), 2022
    The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...

    Novavax COVID-19 vaccine local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than a...

    Executive Summary Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline

    Chest; S0012 (22), 2022
    Background The American College of Chest Physicians Clinical Practice Guideline on the Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions-Comparators-Outcomes (PICO) questions related to the perioperative management of patients who are receiving long-term oral anticoag...

    American Society of Plastic Surgeons Evidence-Based Clinical Practice Guideline: Eyelid Surgery for Upper Visual Field Improvement

    Plast. reconstr. surg; 150 (2), 2022
    A group of experts from different disciplines was convened to develop guidelines for the management of upper visual field impairments related to eyelid ptosis and dermatochalasis. The goal was to provide evidence-based recommendations to improve patient care. A multidisciplinary group of experts represen...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for persons aged 12-17 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for persons aged 12-17 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRADE...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for children aged 6–11 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6–11 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRA...

    COVID-19 advisory committee on immunization practices (ACIP) vaccine recommendations

    The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CD...

    Interim recommendation of the advisory committee on immunization practices for use of the Novavax COVID-19 Vaccine in persons aged ≥18 years: United States, July 2022

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Novavax COVID-19 vaccine

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...

    ACIP evidence to recommendations for use of Novavax COVID-19 vaccine, adjuvanted in adults ages 18 years and older under an emergency use authorization

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), in late 2019 has led to a global pandemic with dramatic societal and economic impact on individual persons and communities. In the United States, more than 89 million cases and more than 1 million COVID-19-associated ...